Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal article
Yin Z. et al, (2023), Cell Rep, 42
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice.
Journal article
Foster WS. et al, (2023), Immunol Cell Biol
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
Journal article
Saunders JE. et al, (2023), EBioMedicine, 90
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.
Journal article
Dijokaite-Guraliuc A. et al, (2023), Cell Rep, 42
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Journal article
Moore SC. et al, (2023), Med (N Y)
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Journal article
Vatzia E. et al, (2023), NPJ Vaccines, 8
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
Journal article
Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
Journal article
McMahon WC. et al, (2023), AIDS, 37, 105 - 112
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
Journal article
van Doremalen N. et al, (2022), NPJ Vaccines, 7
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.
Journal article
Huo J. et al, (2022), Cell Rep
Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.
Journal article
Nyagwange J. et al, (2022), Int J Infect Dis
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Journal article
Dijokaite-Guraliuc A. et al, (2022), Cell Discov, 8
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Journal article
Foster WS. et al, (2022), Cell Rep Med
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Journal article
Madhi SA. et al, (2022), Lancet Infect Dis
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article
Madhavan M. et al, (2022), EBioMedicine